Hexal AG

Hexal AG is a leading German pharmaceutical company specializing in the development, production, and marketing of generic medicines and biosimilars. Founded in 1986, the company has grown to become one of the largest generics manufacturers in Germany, offering a portfolio of over 400 active ingredients and approximately 2,800 products. Hexal is a key brand under the Sandoz Group, which is the global leader in off-patent medicines. The company's portfolio spans a wide range of therapeutic areas, including oncology, immunology, cardiology, and pain management. Hexal is particularly recognized for its pioneering role in the biosimilars market, having launched some of the first biosimilar products in Europe. Following the spin-off of Sandoz from Novartis in late 2023, Hexal continues to operate as a core subsidiary, leveraging its extensive manufacturing footprint in Germany to provide affordable healthcare solutions globally.